March 20-21, 2018
Save to your calendar
Our Research Xchange Forum brings together experts from academia and industry to foster the exchange of ideas and to stimulate dialog about the next generation of interdisciplinary research. Join our discussions and listen to keynote lectures by leading international biopharma R&D experts. Further highlights: The winner and the finalists of "The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy 2018" will present the results of their research.
Keynote Lecture by the Winner and Lectures by the 3 Finalists of "The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy 2018"
Editor for biomedicine
Topic: "How to publish in Science"
Max Planck Institute for Biophysical Chemistry
Managing Director Max Planck Institute for Biophysical Chemistry
Nobel laureate of 2014 in chemistry
*© Peter Badge/Typos1 in cop. with Foundation Lindau Nobel Laureate Meetings
all rights reserved 2017.
apceth Biopharma GmbH
Group leader Preclinical Development
Topic: Mesenchymal stem cells in immunotherapy
Overview: apceth is harnessing the potential of mesenchymal stem cells (MSC), in which the mechanism of therapeutic effects are very different from that of CAR-T cells. The aim is to provide innovative cell-based gene therapies for the treatment of major indications such as cancer, chronic lung and kidney diseases and for immunomodulation.
apceth has created its allogenic therapeutic platform based entirely on the genetic engineering of MSC isolated from healthy donors.
Vector Downstream Process Development Manager
Topic: Retroviral and lentiviral production: development and scaling up of upstream and downstream process steps
Overview: MolMed has implemented a large-scale process to meet the increasing demand for clinical and commercial grade vector production. There is a special focus on identification of challenges in the downstream/purification strategy to ensure efficient contaminant removal and preservation of viral infectivity.
Director of External Studies in Immuno-oncology
Topic: Allogenic approach developed by Servier and the preclinical data of UCART19
Overview: Servier is applying the Cellectis’ TALEN gene editing technology to overcome current limitations and provide an allogeneic, frozen, “off-the-shelf” T cell based medicinal product.
UCART19 is an allogeneic CAR T-cell product candidate being developed for treatment of CD19-expressing hematological malignancies. It is currently being evaluated in a phase 1 clinical trials in relapsed/refractory acute lymphoblastic leukemia (ALL) of adult and pediatric patients. The selection of UCART19 as a candidate was based on the impressive clinical benefits leading to the marketing of the two first autologous CAR T-cell products Kymriah (Novartis) and Yescarta (Kite Gilead).
Assoc. Director of Commercial Development, Autologous Cell Therapies
Topic: Manufacturing strategies for patient scale cell therapies
Overview: The “Future Technologies” business area under the Pharma & Biotech division of Lonza has a focus on personalized medicine & cell therapy. One of the major challenges in these fields is the production of the patient-specific and patient-scale CAR-T cells or stem cells for treatment.
Lonza has partnered with Octane on the Octane CocoonTM platform, which offers a ground-breaking innovation to address this challenge. Unlike current, labor-intensive production methods, this platform has the potential to enable the automated manufacturing of patient-specific cell therapies for maximum efficiency, traceability and scale-up.
37079 Goettingen, Germany
On the A7 freeway (Hannover- Kassel), take the exit bound for Goettingen Nord (72). Then take the first exit to Industriegebiet (industrial zone) and afterwards, the first exit in the traffic circle. At the next light, make a left turn. Sartorius College will be on your left-hand side.
The nearest airports are Hanover, Kassel and Frankfurt in Germany. From there, you can reach Goettingen by train or car. By taxi, it will take about 10 minutes to get from the Goettingen train station to Sartorius College.
Our first Research Xchange Forum about trends and challenges in oncology took place in February 2017. Lectures given by 12 internationally renowned academics and leading biopharma R&D executives provided insights into the latest developments of their specific cancer research and therapy approaches. At this event, we also focused exchanging ideas and enhancing collaboration between academia and industry. This also included a lively panel discussion covering controversial opinions.
Get impressions: review of the 2-day Forum
The registration fee includes admission, gala dinner, all coffee breaks, lunches and the optional plant tour. Advance registration is required.
|Academia||Postdocs/ PhD Students/ |
|Early Bird||395 EUR*||295 EUR*||105 EUR*|
|Regular||595 EUR*||495 EUR*||195 EUR*|
|Group Ticket||Pay for the 1st ticket and get 50% off on every additional registration|
*All prices are excluding VAT
If you should have any questions, do not hesitate to contact us at any time. We would be pleased to help you.
Sartorius Lab Instruments GmbH & Co. KG